(POZN)


NasdaqGS . Currency in USD
People also watch:
PTIEPGNXRIGLNBIXDEPO
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
OpenN/A
Prev CloseN/A
BidN/A x N/A
AskN/A x N/A
Day's RangeN/A - N/A
52wk Rangeundefined - undefined
1y Target EstN/A
Market CapN/A
P/E Ratio (ttm)N/A
BetaN/A
VolumeN/A
Avg Vol (3m)N/A
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Zacks Small Cap Research6 months ago

    ARLZ: A Strong Management Team and Plenty of Capital Makes Aralez a Top Specialty Pharmaceutical Pick…

    On February 5, 2015, Aralez Pharmaceuticals Inc. (ARLZ) announced that the planned merger between Pozen, Inc. and Tribute Pharmaceuticals Canada, Inc. was complete following approval by the shareholders of each company. The strategy behind Aralez is that the company will become a cardiovascular focused specialty pharmaceutical company with support from a pain-focused franchise. As a reminder, in conjunction with the completion of the merger, a group of leading healthcare investors, led by Deerfield Management, has committed up to $350 million in capital for Aralez to fund the anticipated commercial launch of YOSPRALA® and for “future acquisitions”.

  • CNW Group7 months ago

    POZEN And Tribute Combine To Create Aralez Pharmaceuticals Inc.

    POZEN And Tribute Combine To Create Aralez Pharmaceuticals Inc.

  • PR Newswire7 months ago

    POZEN And Tribute Combine To Create Aralez Pharmaceuticals Inc.

    MILTON, Ontario, Feb. 5, 2016 /PRNewswire/ -- Aralez Pharmaceuticals Inc. ("Aralez") today announced the completion of the business combination of POZEN Inc. ("POZEN") and Tribute Pharmaceuticals Canada Inc. ("Tribute") following approval of the transaction by stockholders of POZEN and shareholders of Tribute. The combined company will operate under Aralez Pharmaceuticals Inc. ("Aralez"), a global specialty pharmaceutical company with operations in Canada, Ireland and the United States. As of closing, Aralez has approximately 75 million outstanding shares on a fully diluted basis.